pioglitazone has been researched along with Hyperandrogenism in 16 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin." | 9.19 | Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 9.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "To study the clinical, metabolic and adverse effects of pioglitazone over a period of 6 months in obese adolescent and young adults with polycystic ovary syndrome." | 9.14 | Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. ( Jacob, JJ; Narsing Rao, L; Paul, TV; Rajarathinam, S; Seshadri, MS; Thomas, N, 2009) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 9.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "Treatment with pioglitazone was also associated with higher ovulation rates (P < 0." | 6.71 | Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. ( Brettenthaler, N; De Geyter, C; Huber, PR; Keller, U, 2004) |
| "The reason why hyperinsulinemia produces hyperandrogenism and whether insulin action on the pituitary alters gonadotropin liberation remain unknown." | 5.33 | Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. ( Garmes, HM; Tambascia, MA; Zantut-Wittmann, DE, 2005) |
| " PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin." | 5.19 | Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 5.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "To study the clinical, metabolic and adverse effects of pioglitazone over a period of 6 months in obese adolescent and young adults with polycystic ovary syndrome." | 5.14 | Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. ( Jacob, JJ; Narsing Rao, L; Paul, TV; Rajarathinam, S; Seshadri, MS; Thomas, N, 2009) |
| "One of the treatments for hyperinsulinemic hyperandrogenism in nonobese women is combined androgen receptor blockade (with flutamide; Flu), insulin sensitization (with metformin; Met) plus an estroprogestagen contraceptive." | 5.12 | Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. ( de Zegher, F; del Rio, L; Enríquez, G; Ibáñez, L; López-Bermejo, A; Valls, C, 2007) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 5.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| ", pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production." | 4.93 | Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS. ( Indran, IR; Lee, BH; Yong, EL, 2016) |
| "Female prepubertal rats were treated with equine chorionic gonadotropin (eCG) to induce folliculogenesis, together with dehydroepiandrosterone (DHEA) to induce hyperandrogenism and/or PGZ to evaluate PPARG activation." | 3.91 | Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats. ( Abruzzese, GA; Ferreira, SR; Heber, MF; Motta, AB; Velez, LM, 2019) |
| "To evaluate the effect of metformin and pioglitazone on leutinizing hormone and follicle stimulating hormone receptor mRNA expression, hyperandrogenism and insulin resistance in high fat diet induced and letrozole induced PCOS in rats." | 3.88 | Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. ( Patel, R; Shah, G, 2018) |
| "Treatment with pioglitazone was also associated with higher ovulation rates (P < 0." | 2.71 | Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. ( Brettenthaler, N; De Geyter, C; Huber, PR; Keller, U, 2004) |
| "The reason why hyperinsulinemia produces hyperandrogenism and whether insulin action on the pituitary alters gonadotropin liberation remain unknown." | 1.33 | Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. ( Garmes, HM; Tambascia, MA; Zantut-Wittmann, DE, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Zeng, X | 1 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Patel, R | 1 |
| Shah, G | 1 |
| Velez, LM | 1 |
| Abruzzese, GA | 1 |
| Heber, MF | 1 |
| Ferreira, SR | 1 |
| Motta, AB | 1 |
| Ibáñez, L | 6 |
| Ong, KK | 1 |
| López-Bermejo, A | 5 |
| Dunger, DB | 1 |
| de Zegher, F | 6 |
| Stabile, G | 1 |
| Borrielli, I | 1 |
| Artenisio, AC | 1 |
| Bruno, LM | 1 |
| Benvenga, S | 1 |
| Giunta, L | 1 |
| La Marca, A | 1 |
| Volpe, A | 1 |
| Pizzo, A | 1 |
| Díaz, M | 4 |
| Gallego-Escuredo, JM | 1 |
| Villarroya, F | 1 |
| Indran, IR | 1 |
| Lee, BH | 1 |
| Yong, EL | 1 |
| Cho, LW | 1 |
| Kilpatrick, ES | 1 |
| Keevil, BG | 1 |
| Coady, AM | 1 |
| Atkin, SL | 1 |
| Narsing Rao, L | 1 |
| Jacob, JJ | 1 |
| Paul, TV | 1 |
| Rajarathinam, S | 1 |
| Thomas, N | 1 |
| Seshadri, MS | 1 |
| Sebastiani, G | 1 |
| Sánchez-Infantes, D | 1 |
| Salvador, C | 2 |
| Chacón, MR | 1 |
| Maymó-Masip, E | 1 |
| Vendrell, J | 1 |
| Brettenthaler, N | 1 |
| De Geyter, C | 1 |
| Huber, PR | 1 |
| Keller, U | 1 |
| Ortega-González, C | 1 |
| Luna, S | 1 |
| Hernández, L | 1 |
| Crespo, G | 1 |
| Aguayo, P | 1 |
| Arteaga-Troncoso, G | 1 |
| Parra, A | 1 |
| Garmes, HM | 1 |
| Tambascia, MA | 1 |
| Zantut-Wittmann, DE | 1 |
| del Rio, L | 1 |
| Enríquez, G | 2 |
| Valls, C | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
2 reviews available for pioglitazone and Hyperandrogenism
| Article | Year |
|---|---|
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
Topics: Androgens; Animals; Death Domain Receptor Signaling Adaptor Proteins; Decanoic Acids; Disease Models | 2016 |
10 trials available for pioglitazone and Hyperandrogenism
| Article | Year |
|---|---|
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
Topics: Adiponectin; Adolescent; C-Reactive Protein; Female; Fibrinogen; Hirsutism; Humans; Hyperandrogenism | 2014 |
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Fac | 2016 |
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2009 |
Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Menstr | 2009 |
Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Body Composition; Cyproterone Acetate; Drug Combina | 2011 |
Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Angiopoietin-Like Protein 4; Angiopoietins; Antigen | 2012 |
Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
Topics: Adult; Double-Blind Method; Female; Glucose Intolerance; Hormones; Humans; Hyperandrogenism; Insulin | 2004 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.
Topics: Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Body Composition; Body Mass Index; Carotid | 2007 |
Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.
Topics: Adiponectin; Adolescent; Adult; Double-Blind Method; Female; Flutamide; Humans; Hyperandrogenism; Hy | 2008 |
4 other studies available for pioglitazone and Hyperandrogenism
| Article | Year |
|---|---|
Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats.
Topics: Animals; Body Weight; Carboxymethylcellulose Sodium; Diet, High-Fat; Female; Glucose Tolerance Test; | 2018 |
Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats.
Topics: Animals; Co-Repressor Proteins; Dehydroepiandrosterone; Disease Models, Animal; Estradiol; Female; H | 2019 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Hormone Antagonists; Humans; Hyperandrogenism; Hyperinsulinism; Obesity; | 2005 |